Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant tissue plasminogen activator for acute ischemic stroke.

Amira R Al-Buhairi1, Mohammed M Jan

  • 1Department of Internal Medicine, King Khalid National Guard Hospital, PO Box 9515, Jeddah 21423, Kingdom of Saudi Arabia.

Saudi Medical Journal
|April 9, 2002
PubMed
Summary

Recombinant tissue plasminogen activator is an effective treatment for acute ischemic stroke, but its use remains low. This review critically examines its role as a first-line therapy for stroke patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Next generation sequencing reveals novel homozygous frameshift in <i>PUS7</i> and splice acceptor variants in <i>AASS</i> gene leading to intellectual disability, developmental delay, dysmorphic feature and microcephaly.

Saudi journal of biological sciences·2020
Same author

Parental perceptions of dental health and need for treatment in children with epilepsy: a multicenter cross-sectional study.

Pediatric health, medicine and therapeutics·2018
Same author

Treatment of infantile spasms in Saudi Arabia.

Neurosciences (Riyadh, Saudi Arabia)·2018
Same author

Publications pattern of clinical epilepsy research in Saudi Arabia.

Neurosciences (Riyadh, Saudi Arabia)·2017
Same author

Public awareness of autism spectrum disorder.

Neurosciences (Riyadh, Saudi Arabia)·2017
Same author

Management of convulsive status epilepticus in children: an adapted clinical practice guideline for pediatricians in Saudi Arabia.

Neurosciences (Riyadh, Saudi Arabia)·2017

Area of Science:

  • Neurology
  • Cardiovascular Medicine
  • Emergency Medicine

Background:

  • Stroke is a major cause of death and disability globally, with incidence increasing after age 55.
  • Arterial occlusion is present in most acute stroke cases, highlighting the need for timely recanalization.
  • Recombinant tissue plasminogen activator (rt-PA) offers a safe and effective intravenous treatment for acute ischemic stroke.

Purpose of the Study:

  • To critically evaluate the efficacy and appropriateness of recombinant tissue plasminogen activator (rt-PA) as a first-line treatment for acute ischemic stroke.
  • To review the results of major clinical trials involving rt-PA therapy.

Main Methods:

  • Systematic review and critical analysis of published data on recombinant tissue plasminogen activator (rt-PA) trials.

Related Experiment Videos

  • Evaluation of rt-PA's safety and effectiveness in acute ischemic stroke treatment.

    • Main Results:

    • Recombinant tissue plasminogen activator (rt-PA) is approved and effective, particularly when administered within 3 hours of symptom onset.
    • Despite its benefits, less than 5% of eligible stroke patients currently receive rt-PA treatment.
    • Major rt-PA trials demonstrate its potential to improve outcomes by restoring blood flow.

    Conclusions:

    • The underutilization of recombinant tissue plasminogen activator (rt-PA) for acute ischemic stroke warrants further investigation.
    • Evidence supports rt-PA's role in acute ischemic stroke management, but barriers to its widespread use need addressing.
    • Further analysis of rt-PA trials is crucial to optimize its application as a first-line therapy.